Mon, Mar 2, 2015, 11:51 AM EST - U.S. Markets close in 4 hrs 9 mins

Recent

% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

  • wilderguide wilderguide Nov 1, 2013 2:32 PM Flag

    Comet1 estimated completion

    $$$$
    Nice little write-up on Comet 1 @ targetedoncdotcom...posted 11/1/13
    "The 960-patient trial is under way at 270 sites worldwide and has an estimated primary completion date of March 2014. In preclinical studies, cabozantinib has shown powerful tumoricidal, antimetastatic, and antiangiogenic effects, including extensive apoptosis of malignant cells, decreased tumor invasiveness and metastasis, decreased tumor and endothelial cell proliferation, blockade of metastatic bone lesion progression, and disruption of tumor vasculature."
    GLTA

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
EXEL
2.96+0.03(+1.02%)11:50 AMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.